Personalized Dosing and Pharmacogenomics

Personalized dosing and pharmacogenomics is the topic concerned with tailoring drug exposure to the individual patient, including the use of inherited genetic variation to predict how a person will handle and respond to a medicine. It addresses why a single standard dose produces a wide range of exposures and effects across people, and how patient-specific factors - among them genotype - can be used to anticipate and adjust for that variability.

Definition

Pharmacogenomics is the study of how inherited and acquired genetic variation influences drug response; personalized dosing is the adjustment of drug regimens to individual patient characteristics - including genotype, organ function, and other factors - so that exposure and effect fall within a useful range.

Scope

The topic covers the sources of interindividual variability in drug handling and response, the genetics of drug-metabolising enzymes, transporters, and targets, and the framework of genotype-informed dosing as expressed in implementation guidelines. It is a reference topic describing the science and infrastructure of individualised dosing, not a source of specific dose recommendations.

Core questions

• Why does the same dose produce different exposures and effects in different people?
• Which genetic variants in metabolising enzymes, transporters, and targets affect drug response?
• How is genotype information translated into actionable dosing guidance?
• How common are clinically relevant pharmacogenomic variants across populations?
• How does genotype combine with non-genetic factors in individualising a regimen?

Key concepts

• Interindividual variability in drug response
• Drug-metabolising enzyme polymorphisms
• Metaboliser phenotypes (poor, intermediate, normal, ultrarapid)
• Cytochrome P450 variation
• Pharmacodynamic gene variants
• Genotype-to-phenotype translation
• Genotype-guided dosing guidelines
• Implementation of pharmacogenomic testing

Mechanisms

Drug response varies between people because of differences in pharmacokinetics and pharmacodynamics, a substantial part of which is genetically determined. Variants in genes encoding drug-metabolising enzymes - notably the cytochrome P450 family - alter the rate at which a drug is activated or cleared, producing metaboliser phenotypes that range from poor to ultrarapid and shifting drug exposure accordingly. Variants in transporters change distribution, and variants in drug targets change sensitivity. Pharmacogenomic frameworks translate a measured genotype into a predicted phenotype and then into dosing guidance, so that individuals predicted to over- or under-respond can be identified in advance and their regimens adjusted within evidence-based limits.

Clinical relevance

Pharmacogenomics is increasingly embedded in clinical pharmacy through testing programmes and genotype-informed guidance, and it illustrates how individual biology shapes drug response. As a reference topic it explains the basis and infrastructure of individualised dosing; it describes how dosing is reasoned about and does not provide specific doses, genotype interpretations, or treatment advice for any individual.

Epidemiology

Clinically relevant pharmacogenomic variants are common and unevenly distributed across populations: large-scale sequencing meta-analyses show that functional variation in cytochrome P450 genes is widespread, so that a meaningful proportion of people in any population carry alleles predicted to alter the handling of commonly used drugs.

Evidence & guidelines

Implementation is supported by genotype-based dosing guidelines, including those of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, which provide structured recommendations linking specific genotypes to dosing actions for defined drug-gene pairs. These guidelines are periodically updated as evidence accrues.

History

Observations in the mid-twentieth century that some patients metabolised certain drugs unusually slowly or rapidly gave rise to pharmacogenetics; the sequencing of the human genome and large population studies broadened this into pharmacogenomics. Over time the field moved from describing individual drug-gene relationships to building consortium guidelines and clinical testing programmes that operationalise genotype-informed dosing.

Debates

How broadly should pre-emptive pharmacogenomic testing be deployed?

Genotype-guided dosing has clear value for specific drug-gene pairs, but the cost-effectiveness and clinical yield of testing whole populations pre-emptively versus testing reactively for particular drugs remains debated as implementation evidence accumulates.

Seminal works

• wang-2011
• roden-2019
• swen-2011

Frequently asked questions

What is a metaboliser phenotype?

It is a classification - such as poor, intermediate, normal, or ultrarapid metaboliser - that describes, based on genotype, how quickly a person is predicted to process a drug through a given enzyme, which in turn affects drug exposure.

Does pharmacogenomics replace other dosing factors?

No. Genotype is one input among many; individualised dosing also accounts for organ function, age, weight, comorbidities, and concurrent medicines, and pharmacogenomic guidance is applied within that broader clinical picture.